Cargando…
Clinical outcomes and cognitive impairments between progressive supranuclear palsy and multiple system atrophy
BACKGROUND: Both progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) belong to atypical parkinsonian syndromes. It is important to differentiate these diseases accurately. We compared clinical outcomes and cognitive impairments between PSP and MSA. METHODS: Eighty‐five MSA parkins...
Autores principales: | Jia, Peifei, Zhang, Jinhong, Han, Jiuyan, Ji, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759125/ https://www.ncbi.nlm.nih.gov/pubmed/36409061 http://dx.doi.org/10.1002/brb3.2827 |
Ejemplares similares
-
Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy
por: Mori, Akio, et al.
Publicado: (2019) -
Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy
por: Brown, Jesse A., et al.
Publicado: (2017) -
Clinical Features and Disability Milestones in Multiple System Atrophy and Progressive Supranuclear Palsy
por: Lee, Sang-Wook, et al.
Publicado: (2012) -
Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease
por: Kass-Iliyya, Lewis, et al.
Publicado: (2015) -
Identification of multiple system atrophy mimicking Parkinson’s disease or progressive supranuclear palsy
por: Miki, Yasuo, et al.
Publicado: (2021)